Key factors
sym | ELGX |
exch | US |
MCap | 4218.24K |
Beta | 0.735 |
EPS | -7.27 |
Div date | 0000-00-00 |
Yesterday
sym | ELGX |
exch | US |
close | 0.019 |
50 Day MA | 0.034 |
200 Day MA | 0.473 |
Target Price | 0.88 |
Market Cap Mln | 4.218 |
Share statistics
Shares Outstanding | 19.17M |
Shares Float | 14.12M |
Percent Institutions | 74.71 |
PercentInsiders | 4.693 |
SharesShort | 343.57K |
Short Ratio | 0.91 |
Shares Short Prior Month | 236.44K |
Short Percent | 2.019 |
Income
Revenue TTM | 136.27M |
Revenue Per Share TTM | 7.071 |
Quarterly Revenue Growth YOY | -19.9 |
Gross Profit TTM | 91.08M |
EBITDA | -48.6M |
Diluted Eps TTM | -3.15 |
earning
Operating Margin TTM | -0.33 |
PEGRatio | -0.22 |
EPS Estimate Current Quarter | -0.86 |
EPS Estimate Current Year | -2.41 |
EPS Estimate Next Quarter | -0.62 |
EPS Estimate Next Year | -1.97 |
Earnings Share | -7.27 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2019-03-06 |
Last Split Factor | 1:10 |
business
Enterprise Value Revenue | 1.487 |
Book Value /share | 2.792 |
Price Book MRQ | 0.014 |
Price Sales TTM | 0.003 |
ProfitMargin | -0.44 |
ReturnOnAssetsTTM | -0.09 |
Sector
Gic Group | Health Care Equipment & Services |
Gic Industry | Health Care Equipment & Supplies |
Gic Sector | Health Care |
Gic Sub Industry | Health Care Supplies |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Codes
ISIN | US29266S3040 |
CIK | 1013606 |
Code | ELGX |
CUSIP | 14160K102 |
Employer Id Number | 68-0328265 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2021-01-22 |
is Delisted | 1 |
Delisted Date | 2020-08-20 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 488.0 |
IPODate | 1996-06-20 |
International Domestic | Domestic |
MostRecent Quarter | 2020-06-30 |
Contact
Name | Endologix Inc |
Address | 2 Musick, Irvine, CA, United States, 92618 |
Country Name | USA |
Phone | 949-595-7200 |
Web URL | endologix.com |
Logo URL | /img/logos/US/ELGX.png |
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California. On July 5, 2020, Endologix, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. It is in joint administration with TriVascular Sales LLC.